Scalper1 News
Specialty-drug giant and IBD 50 stock Valeant Pharmaceuticals (VRX) agreed to pay big pharma AstraZeneca (AZN) up to $445 million in a licensing deal for a psoriasis drug candidate that had proved effective but also shown a suicide risk in clinical trials. Valeant agreed to pay AstraZeneca $100 million upfront for brodalumab, and committed up to $170 million in prelaunch milestones and $175 million in sales milestones. As phase three studies in Scalper1 News
Scalper1 News